Chemoprevention of human skin cancer

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 3, 2002, Pages 269-285

  Einspahr, Janine G ^a   Stratton, Steven P ^a   Bowden, G Timothy ^a   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Actinic keratosis (AK); Chemoprevention; Chemoprevention agents; Nonmelanoma skin cancer (NMSC)

Indexed keywords

AROTINOID; BETA CAROTENE; BIOLOGICAL MARKER; CARCINOGEN; ETRETIN; ETRETINATE; FLUOROURACIL; ISOTRETINOIN; RETINOL; SELENIUM; SULFONE; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT;

ACTINIC KERATOSIS; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DYSPLASTIC NEVUS; ERYTHEMA; HISTOLOGY; HUMAN; INFLAMMATION; MELANOMA; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN CANCER; SUNLIGHT; ULTRAVIOLET RADIATION; DIET SUPPLEMENTATION; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; HUMAN; RADIATION-PROTECTIVE AGENTS; SKIN NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.; ULTRAVIOLET RAYS; HUMANS;

EID: 0036008997     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00185-8     Document Type: Review

References (220)

1. Clinical and histologic trends of melanoma
2. Cancer statistics, 2000
3. The pathogenesis of melanoma induced by ultraviolet radiation
4. Effects of topical tretinoin on dysplastic nevi
5. Role of topical tretinoin in melanoma and dysplastic nevi
6. Effect of topical tretinoin under occlusion on atypical naevi
7. Animal models of melanoma: Recent advances and future prospects
8. Ultraviolet A and melanoma: A review
9. Malignant melanoma: A clinical review
10. An overview of skin cancers. Incidence and causation
11. Metastases in dermatological patients with squamous cell carcinoma
12. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up
13. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer
14. Nonmelanoma cancers of the skin
15. Biology of cutaneous squamous cell carcinoma
16. The state-of-the-art in chemoprevention of skin cancer
17. Epidemiology of actinic keratoses and squamous cell carcinoma
18. Cancer precursors
19. Malignant transformation of solar keratoses to squamous cell carcinoma
20. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective
21. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial
22. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis')
23. Precursors to skin cancer
24. Actinic keratosis and squamous cell carcinoma
25. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis
26. Solar keratoses
27. Photocarcinogenesis by ultraviolet A and B
28. Cutaneous photocarcinogenesis
29. Sunlight and the onset of skin cancer
30. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion
31. The scientific basis of skin cancer
32. p53 gene mutations and photocarcinogenesis
33. Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation
34. Effect of UV-irradiation on cell cycle, viability and the expression of p53, gadd153 and gadd45 genes in normal and HPV-immortalized human oral keratinocytes
35. High levels of p53 protein in UV-irradiated normal human skin
36. Dissociation of erythema and p53 protein expression in human skin following UVB irradiation, and induction of p53 protein and mRNA following application of skin irritants
37. Different regulation of p53 stability in UV-irradiated normal and DNA repair deficient human cells
38. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma
39. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin
40. p53 gene mutations in human skin cancers and precancerous lesions: Comparison with immunohistochemical analysis
41. p53 gene mutations in human epithelial skin cancers
42. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers
43. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas
44. Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin
45. Sunburn and p53 in the onset of skin cancer
46. Frequent clones of p53-mutated keratinocytes in normal human skin
47. Abnormalties of p53 protein expression in cutaneous disorders
48. Expression of p53 protein is an early event in ultraviolet light-induced cutaneous squamous cell carcinogenesis
49. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes
50. p53 protein expression in benign and malignant skin tumours
51. Overexpression of p53 protein in basal cell carcinomas of human skin
52. Mutant p53 protein is expression in solar keratosis: An immunohistochemical study
53. Mutant p53 protein is expressed in Bowen's disease
54. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma
55. Immunohistological analysis of P53 expression in human skin tumors
56. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin
57. Role of the Ha-ras oncogene in skin cancer
58. Detection and identification of activated oncogenes in human skin cancers occurring on sun-exposed body sites
59. Sunlight and skin cancer: Inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens
60. Ras gene mutation and amplification in human nonmelanoma skin cancers
61. Oncogene activation in human benign tumors of the skin (keratoacanthomas): Is HRAS involved in differentiation as well as proliferation?
62. Codon 12 Harvey-ras mutations are rare events in non-melanoma human skin cancer
63. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production
64. TNF-alpha and IL-8 are upregulated in the epidermis of normal human skin after UVB exposure: Correlation with neutrophil accumulation and E-selectin expression
65. Solar ultraviolet-induced erythema in human skin and nuclear factor- kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract
66. Redox regulation of NF-kappa B activation
67. Molecular basis of sun-induced premature skin ageing and retinoid antagonism
68. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells
69. Ultraviolet B-induced activated protein-1 activation does not require epidermal growth factor receptor but is blocked by a dominant negative PKClambda/iota
70. Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase
71. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion
72. Inhibition of atypical PKC blocks ultraviolet-induced AP-1 activation by specifically inhibiting ERKs activation
73. Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo
74. The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells
75. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation
76. Complexities of the protein kinase C pathway
77. Diacylglycerol directly stimulates the insulin receptor tyrosine kinase
78. Translocation of protein kinase Cepsilon and protein kinase Cdelta to membrane is required for ultraviolet B-induced activation of mitogen-activated protein kinases and apoptosis
79. Vitamin E analog modulates UVB-induced signaling pathway activation and enhances cell survival
80. H2O2 is an important mediator of UVB-induced EGF-receptor phosphorylation in cultured keratinocytes
81. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation
82. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389
83. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition
84. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
85. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin
86. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression
87. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
88. Aspirin and the potential role of prostaglandins in colon cancer
89. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
90. Cyclooxygenases 1 and 2
91. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials
92. Validation of intermediate end points in cancer research
93. An epidemiologic perspective on biomarkers
94. Recent advances in chemoprevention of cancer
95. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
96. Cancer chemoprevention: Progress and promise
97. Chemoprevention of cancer
98. (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity
99. Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line
100. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: Structure-activity relationship and mechanisms involved
101. Inhibition of ultraviolet B-induced AP-1 activation by theaflavins from black tea
102. Green tea in chemoprevention of cancer
103. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells
104. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB
105. Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanatesm
106. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade
107. A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea - A review
108. Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages
109. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins
110. Green tea and skin - Anticarcinogenic effects
111. Tea and cancer
112. Green tea polyphenols and cancer: Biologic mechanisms and practical implications
113. Antimutagenic and anticarcinogenic activity of tea polyphenols
114. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review
115. Control of ornithine decarboxylase activity in alpha-difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues
116. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
117. Alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin
118. Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis
119. Development of difluoromethylornithine (DFMO) as a chemoprevention agent
120. Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice
121. Prevention by alpha-difluoromethylornithine of skin carcinogenesis and immunosuppression induced by ultraviolet irradiation
122. Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by alpha-difluoromethylornithine
123. Cyclooxygenases: Structural, cellular, and molecular biology
124. Constitutively elevated levels of ornithine and polyamines in mouse epidermal papillomas
125. Polyamines regulate expression of the neoplastic phenotype in mouse skin
126. Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice
127. Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line
128. Alpha-difluoromethylornithine induces apoptosis as well as anti- angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model
129. Effect of polyamine depletion on DNA damage and repair following UV irradiation of HeLa cells
130. Alterations in repair of alkylating agent-induced DNA damage in polyamine-depleted human cells
131. Prevention and therapy of cancer by dietary monoterpenes
132. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation
133. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation
134. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines
135. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice
136. Inhibition of ultraviolet C irradiation-induced AP-1 activity by aspirin is through inhibition of JNKs but not erks or P38 MAP kinase
137. Involvement of prostaglandins in the immune alterations caused by the exposure of mice to ultraviolet radiation
138. Non steroidal anti-inflammatory drugs and colorectal cancer: Is there a way forward?
139. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
140. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
141. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2
142. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells
143. Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells
144. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention
145. Vitamin E and oxidative stress
146. Evidence for the photoprotective effects of vitamin E
147. Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and D-alpha-tocopherol (vitamin E)
148. Topical tocopherol acetate reduces post-UVB, sunburn-associated erythema, edema, and skin sensitivity in hairless mice
149. Photoprotective effect of superoxide-scavenging antioxidants against ultraviolet radiation-induced chronic skin damage in the hairless mouse
150. Modulation of UV-light-induced skin inflammation by D-alpha-tocopherol and L-ascorbic acid: A clinical study using solar simulated radiation
151. Alpha-tocopherol, an inhibitor of epidermal lipid peroxidation, prevents ultraviolet radiation from suppressing the skin immune system
152. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer
153. Retinoids: Present role and future potential
154. Advances in the development of retinoids as chemopreventive agents
155. Retinoids in cancer chemoprevention
156. Vitamin A and retinoids in health and disease
157. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
158. Identification of the AP1-antagonism domain of retinoic acid receptors
159. Role of retinoids in skin cancer treatment and prevention
160. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site
161. Retinoic acid is a negative regulator of AP-1-responsive genes
162. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element
163. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation
164. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid
165. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor
166. Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment
167. Retinoids and demethylating agents - Looking for partners
168. Heparin/heparan sulfate interacting protein gene expression is up-regulated in human colorectal carcinoma and correlated with differentiation status and metastasis
169. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
170. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer
171. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes
172. Differential expression of peroxisome proliferator-activated receptor- alpha, -beta, and -gamma during rat embryonic development
173. Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion
174. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha
175. Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model
176. Keratinocyte differentiation in hyperproliferative epidermis: Topical application of PPARalpha activators restores tissue homeostasis
177. Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis
178. Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3
179. 1 Alpha, 25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin
180. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects
181. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
182. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
183. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway
184. Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin
185. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent
186. Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds
187. Inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin ornithine decarboxylase and protein kinase C by polyphenolics from grapes
188. Effects of isothiocyanates on tumorigenesis by benzo[a]pyrene in murine tumor models
189. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism
190. Effect of alkyl chain length on inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis and DNA methylation by isothiocyanates
191. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds
192. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis
193. PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer
194. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer
195. Changes in skin protection behaviors, attitudes, and sunburn: In a population with the highest incidence of skin cancer in the world
196. High sun protection factor sunscreens in the suppression of actinic neoplasia
197. Reduction of solar keratoses by regular sunscreen use
198. Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study
199. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial
200. An inquiry into the epidemiology of melanoma
201. Effect of sunscreens on UV radiation-induced enhancement of melanoma growth in mice
202. Management of actinic keratoses with topical 5-fluorouracil
203. Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial
204. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: A multicenter clinical trial
205. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial
206. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study
207. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin
208. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study
209. The effects of a novel potent oral retinoid (Rol3-6298) in the treatment of multiple solar keratoses and squamous cell epithelioma
210. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin
211. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: A double-blind, comparative study
212. Etretinate in treatment of actinic keratosis. A double-blind crossover study
213. Cancer, warts, and sunshine in renal transplant patients. A case-control study
214. Effect of a low-fat diet on the incidence of actinic keratosis
215. Relation of antioxidants and level of dietary lipid to epidermal lipid peroxidation and ultraviolet carcinogenesis
216. Ornithine decarboxylase as a target for chemoprevention
217. Chemoprevention of human actinic kerotoses by topical 2-(difluoromethyl)-DL-ornithine
218. UVB irradiation-induced activator protein-1 activation correlates with increased c-fos gene expression in a human keratinocyte cell line
219. Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes
220. Inhibitory effects of deferoxamine on UVB-induced AP-1 transactivation